William E Jones rd,W Waren Suh,May Abdel-Wahab et al.
William E Jones rd et al.
Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread asso...
Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study [0.03%]
辅助外照射对盆腔局限期III期子宫内膜癌患者预后的影响：一项多中心研究
Kevin Albuquerque,Michael Folkert,Jyoti Mayadev et al.
Kevin Albuquerque et al.
Background: Adjuvant therapy choice for women with FIGO stage III endometrial carcinoma (EC) is controversial. We investigate the comparative benefit of adjuvant chemotherapy (CT) alone, radiation therapy alone (RT) or in...
Adjuvant Radiotherapy Versus Wait-and-See Strategy for Pathologic T3 or Margin-Positive Prostate Cancer: A Meta-Analysis [0.03%]
病理T3或切缘阳性前列腺癌的辅助放疗与监测策略的meta分析
M Parvez Shaikh,Fiori Alite,Meng-Jia Wu et al.
M Parvez Shaikh et al.
Objective: To conduct a meta-analysis of the randomized controlled trials (RCTs) comparing adjuvant radiotherapy (ART) to wait-and-see (WS) strategy in pathologic T3 or margin-positive prostate cancer. ...
Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity [0.03%]
三线挽救性化疗治疗复发性宫颈癌疗效欠佳且毒性反应大
Dustin B Manders,Siobhan M Kehoe,David S Miller et al.
Dustin B Manders et al.
Background: Metastatic and recurrent cervical cancer is rarely a curable disease. Systemic chemotherapy is typically recommended for treatment based on clinical trials in the first-line or second-line setting. Rare patien...
Challenges in Management of Squamous Cell Carcinoma of the Anus in New England and Across the United States: A Review of the National Cancer Data Base [0.03%]
美国新英格兰和全美肛门鳞状细胞癌管理面临的挑战：全国癌症数据库文献复习
Victor E Pricolo,Kyle L Viani,Matteo Bonvini et al.
Victor E Pricolo et al.
Background: Management of squamous cell carcinoma of the anus (SCCA) is becoming more relevant, as its incidence continues to increase. The purpose of this study was to evaluate regional and national data to assess trends...
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer [0.03%]
针对血管受侵的交界性或局部晚期胰腺癌的新辅助化疗放疗个体化给药的耐受性和长期结局
Jennifer Y Wo,Andrzej Niemierko,David P Ryan et al.
Jennifer Y Wo et al.
Purpose: We reviewed our experience involving patients with borderline resectable or locally advanced pancreatic cancer, treated with the dose-painted (DP) boost technique to regions of vessel involvement which preclude u...
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival [0.03%]
子宫癌肉瘤的化学免疫治疗与化疗：护理模式及对总生存率的影响分析
Bismarck Odei,Dustin Boothe,Gita Suneja et al.
Bismarck Odei et al.
Objectives: Uterine carcinosarcoma (UCS) is a rare and aggressive cancer with poor survival. Our purpose was to evaluate the patterns-of-care and overall survival (OS) benefit of adjuvant chemoradiation (aCRT) compared wi...
Suboptimal Compliance With National Comprehensive Cancer Network Melanoma Guidelines: Who Is at Risk? [0.03%]
NCCN黑色素瘤指南依从性欠佳的高危因素分析
Andrew M Blakely,Danielle S Comissiong,Michael P Vezeridis et al.
Andrew M Blakely et al.
Background: National Comprehensive Cancer Network (NCCN) melanoma treatment guidelines are based on best available literature. We evaluated NCCN excision margin and sentinel lymph node biopsy (SLNB) guideline adherence to...
Response to Comments by Drs Hamaoka and Beyea on "The Birth of the Illegitimate Linear No-Threshold Model: An Invalid Paradigm for Estimating Risk Following Low-dose Radiation Exposure" [0.03%]
关于Hamaoka和Beyea博士对“低剂量辐射照射风险评估无效的线性无阈值模型起源”的评论的回应
Jeffry A Siegel,Bill Sacks,Charles W Pennington et al.
Jeffry A Siegel et al.
Totally Implantable Venous Access Devices: A Review of Complications and Management Strategies [0.03%]
完全植入式静脉输液港的并发症及管理策略综述
Omidreza Tabatabaie,Gyulnara G Kasumova,Mariam F Eskander et al.
Omidreza Tabatabaie et al.
Objective: Totally implantable venous access devices (portacaths, or "ports"), are widely used for intermittent central venous access especially for cancer patients. Although ports have a superior safety margin compared w...